RxDoctor Payments DataLook up a doctor →

Vance Wilson, MD

Interventional Cardiology · Daytona Beach, FLNPI 1487614947

Payments from drug & device makers

$746,325in general payments, 2019–2025

Across 527 payments — averaging $1416.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$218K
  • Janssen Research & Development, LLC$194K
  • Pfizer$160K
  • Novartis$57K
  • Akcea Therapeutics, Inc.$21K
  • E.r. Squibb & Sons, L.L.C.$18K
  • plus $78K from 36 others

What the payments were for

  • Consulting fees$16,7166%
  • Speaking & faculty fees$238,61580%
  • Travel & lodging$36,13912%
  • Food & beverage$8,1633%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$746,325 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$391,481
Medicare patients
1,071
Services billed
5,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban733$818,911
EntrestoSacubitril/Valsartan187$231,672
Repatha SureclickEvolocumab170$190,196
FarxigaDapagliflozin Propanediol95$103,279
JardianceEmpagliflozin43$61,536
Praluent PenAlirocumab75$58,599
XareltoRivaroxaban19$30,618
VascepaIcosapent Ethyl15$17,009
Ezetimibe524$15,239
Atorvastatin Calcium667$8,926
Repatha SyringeEvolocumab13$7,331
Rosuvastatin Calcium454$7,226
Metoprolol Succinate518$7,113
Nebivolol Hcl120$6,163
BrilintaTicagrelor11$5,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160,284$818,911733 claims
NovartisEntresto$57,298$231,672187 claims
AstraZenecaFarxiga, Brilinta$15,212$108,607106 claims
Boehringer IngelheimJardiance$93$61,53643 claims
Johnson & JohnsonXarelto$32$30,61819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →